HEOR News Roundup

Tuesday, December 17, 2019 | Issue 482

Subscribe Contact Advertise HEOR & RWE Marketplace

Sponsored by

Venture Capitalist Chimes
in on Drug Pricing Debate

Bruce Booth, Atlas Venture partner, offers several suggestions for future drug pricing reform in a recent article published on Forbes.

Read More

NPC Responds to ICER’s Non-Drug Topics for 2020

Article: Organizations Must Balance Cost-Effectiveness Analysis, Patient Centricity

Senate Confirms Hahn to Head FDA

Report Highlights Pharma Trends to Watch for in 2020




Health Economics for Non-Health-Economists

December 17-18 | Brussels, Belgium




RWE & Regulatory in 21st Century Cures: Where are we and where are we going?

December 17

Syndicated Reports
Pharmacy Benefit Management (PBM) – Industry Size 2019, Market Opportunities, Share Analysis up to 2025
Democrats and Drug Pricing
White Papers
Health Economics in China: Changing Pharmaceutical Pricing and Reimbursement
The Growing Influence of the Institute of Clinical and Economic Review on Payer Decisions in the US
  Sr. Manager Health Economics, Outcomes Research (HEOR), Value Demonstration Associate Director, Health Economics and Outcomes Research (HEOR) Research Manager (PS30792) Senior Director, Life Sciences Pricing and Market Access (focus HEOR)  

Share this newsletter!